Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

Nory Holle, Ping Wu, MBBS, MSc, Charlotte Pawlyn, MD, Radovan Saso, MD, MPhil, PhD, Jennifer G. Treleaven, MD, Michael Potter, MD PhD, Mark E Ethell, MD, Bronwen E. Shaw, MD PhD, Walter M Gregory, PhD, Sandra Croockewit, MD, Gareth J. Morgan, MD PhD, Faith E. Davies, MD

Blood (2012) 120 (21): 3125.

https://doi.org/10.1182/blood.V120.21.3125.3125

Published: 2012

Journal Articles

The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Radovan Saso, MD, MPhil, PhD, Kevin D Boyd, MB.BS, Kabir Mohammed, Ping Wu, Jennifer Treleaven, Faith E. Davies, MD, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 1348.

https://doi.org/10.1182/blood.V116.21.1348.1348

Published: 2010

Journal Articles

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care.

Girish Ravindranathan, MRCP, Vaia Grigoriadou, MRCP, Radovan Saso, MD, PhD, Shelley Dolan, MSc, PhD, Mark Ethell, MRCP, MRCPath, Michael Potter, FRCP, FRCPath, Jennifer Treleaven, FRCP, FRCPath, Gareth Morgan, FRCP, FRCPath

Blood (2006) 108 (11): 5289.

https://doi.org/10.1182/blood.V108.11.5289.5289

Published: 2006

Journal Articles

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

Gareth J. Morgan, PhD, Stephen Schey, MD, Ping Wu, M. Srikanth, MD, Karen J. Phekoo, Matthew W. Jenner, MD, Sharon Dines, Radovan Saso, MD, Faith E. Davies, MD

Blood (2006) 108 (11): 3555.

https://doi.org/10.1182/blood.V108.11.3555.3555

Published: 2006

Journal Articles

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).

Faith E. Davies, MD, Ping Wu, M. Srikanth, MD, Matthew W. Jenner, MD, Sharon Dines, Radovan Saso, MD, Gareth J. Morgan, PhD

Blood (2006) 108 (11): 3537.

https://doi.org/10.1182/blood.V108.11.3537.3537

Published: 2006

NARROW

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care.

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).

Email alerts

ASH Publications

American Society of Hematology

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care.

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only